Charles Hart, PhD
Exec Dir, Catalyst Program
Innovation Ventures
Chancellor/EVC/FAS

Education & Training

Show all (4) Hide

• Postdoc Molecular Biology Université de Strasbourg, France 1990
• PhD Molecular Biology and Genetics Yale University 1987
• MS Developmental Biology Stanford University 1980
• AB Cell Biology University of California, Berkeley 1977

Publications (52)

Top publication keywords:
Hypoxia-Inducible Factor 1, alpha SubunitThiophenesPhosphoramide MustardsGenes, HomeoboxUreaXenograft Model Antitumor AssaysAntineoplastic AgentsCell HypoxiaProtein KinasesIfosfamideHypoxiaNitroimidazolesCarcinoma, Pancreatic DuctalProdrugsSpheroids, Cellular

• Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
  Oncotarget 2024 Yoon C, Chang KK, Lee JH, Tap WD, Hart CP, Simon MC, Yoon SS
• Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
  JCI insight 2023 Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, …
• Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.
  Molecular pharmacology 2019 Hunter FW, Devaux JBL, Meng F, Hong CR, Khan A, Tsai P, Ketela TW, Sharma I, Kakadia PM, Marastoni S, Shalev Z, Hickey AJR, Print CG, Bohlander SK, Hart CP, Wouters BG, Wilson WR
• Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
  JCI insight 2018 Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, …
• Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.
  Neuro-oncology 2018 Brenner A, Zuniga R, Sun JD, Floyd J, Hart CP, Kroll S, Fichtel L, Cavazos D, Caflisch L, Gruslova A, Huang S, Liu Y, Lodi A, Tiziani S

Show all (47 more) Hide

• Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models.
  Translational oncology 2018 Kumar S, Sun JD, Zhang L, Mokhtari RB, Wu B, Meng F, Liu Q, Bhupathi D, Wang Y, Yeger H, Hart C, Baruchel S
• Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice.
  Cancer research 2018 Matsumoto S, Kishimoto S, Saito K, Takakusagi Y, Munasinghe JP, Devasahayam N, Hart CP, Gillies RJ, Mitchell JB, Krishna MC
• Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
  Antioxidants & redox signaling 2017 Takakusagi Y, Kishimoto S, Naz S, Matsumoto S, Saito K, Hart CP, Mitchell JB, Krishna MC
• A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model.
  Translational oncology 2017 Hajj C, Russell J, Hart CP, Goodman KA, Lowery MA, Haimovitz-Friedman A, Deasy JO, Humm JL
• Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.
  Tomography (Ann Arbor, Mich.) 2016 Stokes AM, Hart CP, Quarles CC
• Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Duran R, Mirpour S, Pekurovsky V, Ganapathy-Kanniappan S, Brayton CF, Cornish TC, Gorodetski B, Reyes J, Chapiro J, Schernthaner RE, Frangakis C, Lin M, Sun JD, Hart CP, Geschwind JF
• Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
  Oncotarget 2016 Yoon C, Chang KK, Lee JH, Tap WD, Hart CP, Simon MC, Yoon SS
• MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts.
  PloS one 2016 Zhang X, Wojtkowiak JW, Martinez GV, Cornnell HH, Hart CP, Baker AF, Gillies R
• Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
  Cancer biology & therapy 2016 Sun JD, Liu Q, Ahluwalia D, Ferraro DJ, Wang Y, Jung D, Matteucci MD, Hart CP
• Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P, Jacamo R, Ma H, Konoplev S, McQueen T, Volgin A, Protopopova M, Mu H, Lee J, Bhattacharya PK, Marszalek JR, Davis RE,…
• Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.
  American journal of cancer research 2015 Sun JD, Ahluwalia D, Liu Q, Li W, Wang Y, Meng F, Bhupathi D, Matteucci MD, Hart CP
• Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
  BMC cancer 2015 Meng F, Bhupathi D, Sun JD, Liu Q, Ahluwalia D, Wang Y, Matteucci MD, Hart CP
• TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Peeters SG, Zegers CM, Biemans R, Lieuwes NG, van Stiphout RG, Yaromina A, Sun JD, Hart CP, Windhorst AD, van Elmpt W, Dubois LJ, Lambin P
• Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302.
  Cancer & metabolism 2015 Wojtkowiak JW, Cornnell HC, Matsumoto S, Saito K, Takakusagi Y, Dutta P, Kim M, Zhang X, Leos R, Bailey KM, Martinez G, Lloyd MC, Weber C, Mitchell JB, Lynch RM, Baker AF, Gatenby RA, Rejniak KA, Hart…
• Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
  Cancer biology & therapy 2015 Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, Bhupathi D, Ruprell AS, Hart CP
• Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
  PloS one 2014 Bailey KM, Cornnell HH, Ibrahim-Hashim A, Wojtkowiak JW, Hart CP, Zhang X, Leos R, Martinez GV, Baker AF, Gillies RJ
• Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
  PloS one 2014 Takakusagi Y, Matsumoto S, Saito K, Matsuo M, Kishimoto S, Wojtkowiak JW, DeGraff W, Kesarwala AH, Choudhuri R, Devasahayam N, Subramanian S, Munasinghe JP, Gillies RJ, Mitchell JB, Hart CP, Krishna …
• Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Portwood S, Lal D, Hsu YC, Vargas R, Johnson MK, Wetzler M, Hart CP, Wang ES
• Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
  Molecular cancer therapeutics 2013 Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, De Bryune E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K
• Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.
  Blood 2012 Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM
• TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
  Cancer chemotherapy and pharmacology 2012 Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP
• Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP
• Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
  Molecular cancer therapeutics 2011 Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP
• 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.
  Journal of medicinal chemistry 2011 Duan JX, Cai X, Meng F, Sun JD, Liu Q, Jung D, Jiao H, Matteucci J, Jung B, Bhupathi D, Ahluwalia D, Huang H, Hart CP, Matteucci M
• Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
  Blood 2010 Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K
• Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.
  Journal of medicinal chemistry 2008 Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M
• A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.
  Cancer chemotherapy and pharmacology 2007 Meng F, Cai X, Duan J, Matteucci MG, Hart CP
• ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation.
  Anti-cancer drugs 2007 Meng F, Nguyen XT, Cai X, Duan J, Matteucci M, Hart CP
• Finding the target after screening the phenotype.
  Drug discovery today 2005 Hart CP
• Selection of estrogen receptor beta- and thyroid hormone receptor beta-specific coactivator-mimetic peptides using recombinant peptide libraries.
  Molecular endocrinology (Baltimore, Md.) 2000 Northrop JP, Nguyen D, Piplani S, Olivan SE, Kwan ST, Go NF, Hart CP, Schatz PJ
• Potent inhibitory ligands of the GRB2 SH2 domain from recombinant peptide libraries.
  Cellular signalling 1999 Hart CP, Martin JE, Reed MA, Keval AA, Pustelnik MJ, Northrop JP, Patel DV, Grove JR
• Genetic recombination as a reporter for screening steroid receptor agonists and antagonists.
  Analytical biochemistry 1998 Dias JM, Go NF, Hart CP, Mattheakis LC
• Homeotic transformation of the occipital bones of the skull by ectopic expression of a homeobox gene.
  Nature 1992 Lufkin T, Mark M, Hart CP, Dollé P, LeMeur M, Chambon P
• Genetic linkage analysis of the murine developmental mutant velvet coat (Ve) and the distal chromosome 15 developmental genes Hox-3.1, Rar-g, Wnt-1, and Krt-2.
  The Journal of experimental zoology 1992 Hart CP, Compton JG, Langley SH, Hunihan L, LeClair KP, Zelent A, Roderick TH, Ruddle FH
• The developmental expression pattern of a new murine homeo box gene: Hox-2.5.
  Developmental biology 1989 Bogarad LD, Utset MF, Awgulewitsch A, Miki T, Hart CP, Ruddle FH
• The Hox-2 homeo box gene complex on mouse chromosome 11 is closely linked to Re.
  Genetics 1988 Hart CP, Dalton DK, Nichols L, Hunihan L, Roderick TH, Langley SH, Taylor BA, Ruddle FH
• Sequence analysis of the murine Hox-2.2, -2.3, and -2.4 homeo boxes: evolutionary and structural comparisons.
  Genomics 1987 Hart CP, Fainsod A, Ruddle FH
• Polypurine/polypyrimidine sequence elements of the murine homeo box loci, Hox-1, -2 and -3.
  Nucleic acids research 1987 Hart CP, Bogarad LD, Fainsod A, Ruddle FH
• Homeo box genes in murine development.
  Current topics in developmental biology 1987 Fienberg AA, Utset MF, Bogarad LD, Hart CP, Awgulewitsch A, Ferguson-Smith A, Fainsod A, Rabin M, Ruddle FH
• Cognate homeo-box loci mapped on homologous human and mouse chromosomes.
  Proceedings of the National Academy of Sciences of the United States of America 1986 Rabin M, Ferguson-Smith A, Hart CP, Ruddle FH
• Spatial restriction in expression of a mouse homoeo box locus within the central nervous system.
  Nature 1986 Awgulewitsch A, Utset MF, Hart CP, McGinnis W, Ruddle FH
• Homeo box gene complex on mouse chromosome 11: molecular cloning, expression in embryogenesis, and homology to a human homeo box locus.
  Cell 1985 Hart CP, Awgulewitsch A, Fainsod A, McGinnis W, Ruddle FH
• Two homoeo box loci mapped in evolutionarily related mouse and human chromosomes.
  Nature 1985 Rabin M, Hart CP, Ferguson-Smith A, McGinnis W, Levine M, Ruddle FH
• Mammalian homeo box genes.
  Cold Spring Harbor symposia on quantitative biology 1985 Ruddle FH, Hart CP, Awgulewitsch A, Fainsod A, Utset M, Dalton D, Kerk N, Rabin M, Ferguson-Smith A, Fienberg A
• Structural and functional aspects of the mammalian homeo box sequences
  Trends in Genetics 1985 F.H. Ruddle, C.P. Hart and W. McGinnis.
• Molecular cloning and chromosome mapping of a mouse DNA sequence homologous to homeotic genes of Drosophila.
  Cell 1984 McGinnis W, Hart CP, Gehring WJ, Ruddle FH
• Molecular cloning and chromosome assignment of murine N-ras.
  Nucleic acids research 1984 Ryan J, Hart CP, Ruddle FH